Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats

European Journal of Pharmacology

Volumn 498, Issue 1-3, 2004, Pages 195-202

  Nemcsik, János ^a   Kordás, Krisztina ^a   Egresits, József ^a   László, Ferenc ^a   László, Ferenc A ^b   Pávó, Imre ^c   Morschl, Éva ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Experimental angina; Pathogenesis of myocardial ischaemia; Platelet activating factor; Synergistic interaction; Vasopressin

Indexed keywords

ADRENALIN; ARGIPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 (O METHYLTYROSINE)]; GINKGOLIDE B; ORNIPRESSIN; PHENTOLAMINE; THROMBOCYTE ACTIVATING FACTOR; VASOPRESSIN;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; ELECTROCARDIOGRAM; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; ST SEGMENT; ST SEGMENT DEPRESSION;

ANGINA PECTORIS; ANIMALS; ARGININE VASOPRESSIN; BLOOD PRESSURE; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; EPINEPHRINE; GINKGOLIDES; HEART RATE; HORMONE ANTAGONISTS; INJECTIONS, INTRAVENOUS; LACTONES; MALE; MYOCARDIAL ISCHEMIA; ORNIPRESSIN; PHENTOLAMINE; PLATELET ACTIVATING FACTOR; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; TIME FACTORS; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 4444225873     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.057     Document Type: Article

References (42)

1. W.A. Boyle III, and L.D. Segel Direct cardiac effects of vasopressin and their reversal by a vascular antagonist Am. J. Physiol. 251 1986 H734 H741
2. W.A. Boyle III, and L.D. Segel Attenuation of vasopressin-mediated coronary constriction and myocardial depression in the hypoxic heart Circ. Res. 66 1990 710 721
3. W.A. Bax, P.H. Van der Graaf, W.B. Stam, E. Bos, D. Nisato, and P.R. Saxena [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists Eur. J. Pharmacol. 285 1995 199 202
4. P. Braquet BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists Prostaglandins 30 1985 687 699
5. A.W. Cowley Jr., E.Q. Quillen Jr., and M.M. Skelton Role of vasopressin in cardiovascular regulation Fed. Proc. 42 1983 3170 3176
6. G. Feuerstein, R. Rabinovici, J. Leor, J.D. Winkler, and S. Vonhof Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors J. Lipid Mediators Cell Signal. 15 1997 255 284
7. K. Harada, Y. Fukata, A. Miwa, S. Kaneta, H. Fukushima, and N. Ogawa Effect of KRN2391, a novel vasodilator, on various experimental anginal models in rats Jpn. J. Pharmacol. 63 1993 35 39
8. N. Hatano, K. Nakatsui, I. Nose, and M. Shimizu Effects of antianginal agents on electrocardiographic change induced with vasopressin in rats Pharmacometrics 19 1980 311 318
9. Y. Hiramatsu, A. Izumi, T. Tezuka, and Y. Kurosawa Antagonizing substances obtained from whale heart extract to vasopressin induced myocardial hypoxia Jpn. J. Pharmacol. 20 1970 313 319
10. C.V. Jackson, W.A. Schumacher, S.L. Kunkel, E.M. Driscoll, and B.R. Lucchesi Platelet-activating factor and the release of a platelet-derived coronary artery vasodilator substance in the canine Circ. Res. 58 1986 218 229
11. S. Jard Mechanisms of action of vasopressin and vasopressin antagonists Kidney Inter., Suppl. 26 1988 S38 S43
12. A. Karasawa, K. Kubo, K. Shuto, T. Oka, and N. Nakamizo Antianginal effects of the new calcium antagonist benidipine hydrochloride in anesthetized rats and spontaneously hypertensive rats. Electrocardiographic study Arzneim.-Forsch. 38 1988 1702 1707
13. Y. Kita, R. Ozaki, S. Sakai, T. Sugimoto, Y. Hirasawa, M. Ohtsuka, H. Senoh, K. Yoshid, and K. Maeda Antianginal effects of FK409, a new spontaneous NO releaser Br. J. Pharmacol. 113 1994 1137 1140
14. M. Kruszynski, B. Lammer, M. Manning, J. Seto, J. Haldar, and W.H. Sawyer [1-(Beta-mercapto-beta-cyclopentamethylenepropionic acid)-2-(O-methyl)tyrosine] arginine-vasopressin and [1(beta-mercapto-beta, beta- cyclopentamethylenepropionic acid)] arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin J. Med. Chem. 23 1980 364 368
15. K. Lande, K. Gjesdal, E. Fonstelein, S.E. Kjeldsen, and I. Eide Effect of adrenaline infusion on platelet number, volume and release reaction Thromb. Haemost. 54 1985 450 453
16. F. László, and B.J.R. Whittle Constitutive nitric oxide modulates the injurious actions of vasopressin on rat intestinal microcirculation in acute endotoxaemia Eur. J. Pharmacol. 260 1994 265 268
17. F.A. László, F. László, and D. De Wied Pharmacology and clinical perspectives of vasopressin antagonists Pharmacol. Rev. 43 1991 73 108
18. F. László, B.J.R. Whittle, and S. Moncada Interactions of constitutive nitric oxide with PAF and thromboxane on rat intestinal vascular integrity in acute endotoxaemia Br. J. Pharmacol. 113 1994 1131 1136
19. S. Lethagen, L. Olofsson, K. Frick, E. Berntorp, and S. Bjorkman Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo Haemophilia 6 2000 15 20
20. E.B. Loucks, P. Symersky, and A.K. Qayumi Platelet-activating factor antagonism: a new concept in the management of regional myocardial ischemia-reperfusion injury J. Invest. Surg. 10 1997 321 338
21. R.H. Michell, C.J. Kirk, and M.M. Billah Hormonal stimulation of phosphatidyl-inositol breakdown with particular reference to the hepatic effects of vasopressin Biochem. Soc. Trans. 7 1979 861 865
22. M.D. Mills, H.B. Burchell, R.L. Parker, and B.R. Kirklin Myocardial infarction and sudden deaths following the administration of pitressin; additional electrocardiographic study in 100 patients given pitressin for cholecystography Proc. Staff Meet. Mayo Clin. 24 1949 254 271
23. G. Montrucchio, G. Camussi, C. Tetta, G. Emanuelli, F. Orzan, L. Libero, and A. Brusca Intravascular release of platelet-activating factor during atrial pacing Lancet 2 1986 293
24. T. Mori, Y. Ishigai, A. Fukuzawa, K. Chiba, and T. Shibano Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model Br. J. Pharmacol. 116 1995 1668 1672
25. P.L. Padfield, J.J. Brown, A.F. Lever, J.J. Morton, and J.I. Robertson Changes of vasopressin in hypertension: cause or effect? Lancet 1 1976 1255 1257
26. P.J. Piper, and A.G. Stewart Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists Br. J. Pharmacol. 90 1987 771 783
27. J.L. Rouleau, M. Packer, L. Moye, J. de Champlain, D. Bichet, M. Klein, J.R. Rouleau, B. Sussex, J.M. Arnold, and F. Sestier Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril J. Am. Coll. Cardiol. 24 1994 583 591
28. A. Ruskin Pitressin test of coronary insufficiency Am. Heart J. 34 1947 569 580
29. T. Shimizu, Z. Honda, M. Nakamura, H. Bito, and T. Izumi Platelet-activating factor receptor and signal transduction Biochem. Pharmacol. 44 1992 1001 1008
30. I.L. Slotnik, and J.D. Teigland Cardiac accidents following vasopressin injection (pitressin) JAMA 146 1951 1126 1129
31. B.E. Sobel Acute myocardial infarction J.C. Bennett F. Plum Cecil Textbook of Medicine 20th edition 1996 WB Saunders Philadelphia 301 316
32. E.J. Sybertz, R.W. Watkins, T. Baum, K. Pula, and M. Rivelli Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog J. Pharmacol. Exp. Ther. 232 1985 156 162
33. A. Tahara, J. Tsukada, Y. Tomura, K. Wada, T. Kusayama, N. Ishii, T. Yatsu, W. Uchida, and N. Taniguchi Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells Peptides 10 2002 1809 1816
34. M. Thibonnier, and M. Woloschak Platelet aggregation and vasopressin receptors in patients with diabetes mellitus Proc. Soc. Exp. Biol. Med. 188 1988 149 152
35. M.E. Thomas, A.H. Osmani, and M.C. Scrutton Some properties of the human platelet vasopressin receptor Thromb. Res. 32 1983 557 566
36. W. Uchida, K. Shibasaki, M. Asano, and T. Takenaka Antianginal effects of YM-16151-4 in various experimental angina models J. Cardiovasc. Pharmacol. 21 1993 701 708
37. J.E. Udelson, W.B. Smith, G.H. Hendrix, C.A. Painchaud, M. Ghazzi, I. Thomas, J.K. Ghali, P. Selaru, F. Chanoine, M.L. Pressler, and M.A. Konstam Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2001 2417 2423
38. Cs. Varga, I. Pávó, D. Lamarque, Z. Szepes, J. Kiss, G. Karácsony, F.A. László, and F. László Endogenous vasopressin increases acute endotoxin shock-provoked gastrointestinal mucosal injury in the rat Eur. J. Pharmacol. 352 1998 257 261
39. D. Vittet, A. Rondot, B. Cantau, J.M. Launay, and C. Chevillard Nature and properties of human platelet vasopressin receptors Biochem. J. 233 1986 631 636
40. C.L. Wainwright, J.R. Parratt, and M. Bigaud The effects of PAF antagonists on ischaemia and reperfusion arrhythmias and ischaemia-induced platelet aggregation Biomed. Biochim. Acta 47 1988 S224 S227
41. T. Wun, T. Paglieroni, and N.A. Lachant Physiologic concentrations of arginine vasopressin activate human platelets in vitro Br. J. Haematol. 92 1996 968 972
42. + exchange inhibitor, on myocardial ischemia and experimental angina models in rats Jpn. J. Pharmacol. 84 2000 196 205